glp-1 obesity drugs pipeline What is the for future medications for obesity? In 5 years, obesity drugs
Description
doi:10.1161/CIRCULATIONAHA.122.059595 12
Yet, many myths surround who should be prescribed these drugs, how they work and what they can and cannot do
241 GLP-1(936) retains its ability to inhibit glucagon secretion even after GLP-1R inactivation, suggesting that its mechanism of action may not be entirely dependent on the GLP-1R
Many thanks for the great work!
16 Vomiting more often supports evaluation of patients for diabetic gastroparesis compared to other symptoms
Ovarian hyperandrogenism is observed in approximately 90% of patients with PCOS
